154 related articles for article (PubMed ID: 9613756)
1. Treatment of restless leg syndrome with pergolide--an open clinical trial.
Winkelmann J; Wetter TC; Stiasny K; Oertel WH; Trenkwalder C
Mov Disord; 1998 May; 13(3):566-9. PubMed ID: 9613756
[TBL] [Abstract][Full Text] [Related]
2. One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome?
Trenkwalder C; Collado Seidel V; Kazenwadel J; Wetter TC; Oertel W; Selzer R; Kohnen R
Mov Disord; 2003 Oct; 18(10):1184-9. PubMed ID: 14534925
[TBL] [Abstract][Full Text] [Related]
3. Low-dose pramipexole in the management of restless legs syndrome. An open label trial.
Stiasny-Kolster K; Oertel WH
Neuropsychobiology; 2004; 50(1):65-70. PubMed ID: 15179023
[TBL] [Abstract][Full Text] [Related]
4. [Effect of high dose pergolide mesilate on restless legs syndrome associated with Parkinson disease].
Imamura A; Tsuboi Y; Tanaka M; Obata T; Yamada T
Rinsho Shinkeigaku; 2007 Apr; 47(4):156-9. PubMed ID: 17511286
[TBL] [Abstract][Full Text] [Related]
5. Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome.
García-Borreguero D; Kohnen R; Högl B; Ferini-Strambi L; Hadjigeorgiou GM; Hornyak M; de Weerd AW; Happe S; Stiasny-Kolster K; Gschliesser V; Egatz R; Cabrero B; Frauscher B; Trenkwalder C; Hening WA; Allen RP
Sleep Med; 2007 Aug; 8(5):455-63. PubMed ID: 17543579
[TBL] [Abstract][Full Text] [Related]
6. [Therapy of idiopathic and uremic restless legs syndrome].
Trenkwalder C; Stiasny K; Oertel WH
Nervenarzt; 1996 Apr; 67(4):265-76. PubMed ID: 8684504
[TBL] [Abstract][Full Text] [Related]
7. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
[TBL] [Abstract][Full Text] [Related]
8. Transverse myelitis associated with restless legs syndrome and periodic movements of sleep responsive to an oral dopaminergic agent but not to intrathecal baclofen.
Brown LK; Heffner JE; Obbens EA
Sleep; 2000 Aug; 23(5):591-4. PubMed ID: 10947026
[TBL] [Abstract][Full Text] [Related]
9. Low dosage of pergolide in the treatment of restless legs syndrome.
Noël S; Korri H; Vanderheyden JE
Acta Neurol Belg; 1998 Mar; 98(1):52-3. PubMed ID: 9606442
[No Abstract] [Full Text] [Related]
10. [Restless legs: recent advances in basic research and therapy].
Sieb JP
Med Monatsschr Pharm; 2010 Apr; 33(4):133-9. PubMed ID: 20429403
[TBL] [Abstract][Full Text] [Related]
11. Restless legs syndrome and its treatment by dopamine agonists.
Stiasny K; Wetter TC; Trenkwalder C; Oertel WH
Parkinsonism Relat Disord; 2000 Nov; 7(1):21-25. PubMed ID: 11008192
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome.
Bliwise DL; Freeman A; Ingram CD; Rye DB; Chakravorty S; Watts RL
Sleep Med; 2005 Mar; 6(2):141-7. PubMed ID: 15716217
[TBL] [Abstract][Full Text] [Related]
13. A six-month study of pergolide and levodopa in de novo Parkinson's disease patients.
Kulisevsky J; López-Villegas D; García-Sánchez C; Barbanoj M; Gironell A; Pascual-Sedano B
Clin Neuropharmacol; 1998; 21(6):358-62. PubMed ID: 9844794
[TBL] [Abstract][Full Text] [Related]
14. Pergolide: treatment of choice in Restless Legs Syndrome (RLS) and Nocturnal Myoclonus Syndrome (NMS). Longterm follow up on pergolide. Short communication.
Staedt J; Hünerjäger H; Rüther E; Stoppe G
J Neural Transm (Vienna); 1998; 105(2-3):265-8. PubMed ID: 9660104
[TBL] [Abstract][Full Text] [Related]
15. Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazid.
Eisensehr I; Ehrenberg BL; Rogge Solti S; Noachtar S
J Neurol; 2004 May; 251(5):579-83. PubMed ID: 15164191
[TBL] [Abstract][Full Text] [Related]
16. Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients.
Earley CJ; Allen RP
Sleep; 1996 Dec; 19(10):801-10. PubMed ID: 9085489
[TBL] [Abstract][Full Text] [Related]
17. Polysomnographic and pharmacokinetic findings in levodopa-induced augmentation of restless legs syndrome.
Vetrugno R; Contin M; Baruzzi A; Provini F; Plazzi G; Montagna P
Mov Disord; 2006 Feb; 21(2):254-8. PubMed ID: 16200540
[TBL] [Abstract][Full Text] [Related]
18. High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study.
Arnold G; Gasser T; Storch A; Lipp A; Kupsch A; Hundemer HP; Schwarz J
Arch Gerontol Geriatr; 2005; 41(3):239-53. PubMed ID: 16029905
[TBL] [Abstract][Full Text] [Related]
19. Treatment of idiopathic restless legs syndrome (RLS) with the D2-agonist cabergoline--an open clinical trial.
Stiasny K; Röbbecke J; Schüler P; Oertel WH
Sleep; 2000 May; 23(3):349-54. PubMed ID: 10811379
[TBL] [Abstract][Full Text] [Related]
20. Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa.
Staedt J; Wassmuth F; Ziemann U; Hajak G; Rüther E; Stoppe G
J Neural Transm (Vienna); 1997; 104(4-5):461-8. PubMed ID: 9295178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
